scholarly journals Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis

2017 ◽  
Vol 69 (10) ◽  
pp. 1526-1534 ◽  
Author(s):  
Huifeng Yun ◽  
Fenglong Xie ◽  
Randall N. Beyl ◽  
Lang Chen ◽  
James D. Lewis ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents ◽  
Medicare Patients

scholarly journals Correction: Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0146633
Author(s):  
Ingunn Fride Tvete ◽  
Bent Natvig ◽  
Jørund Gåsemyr ◽  
Nils Meland ◽  
Marianne Røine ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Regression Analysis ◽  
Biologic Agents ◽  
Multiple Treatment ◽  
Treatment Comparison ◽  
Multiple Treatment Comparison

Biologic Agents for Rheumatoid Arthritis

2009 ◽  
Vol 32 (Supplement) ◽  
pp. S4-S17 ◽  
Author(s):  
Nadera J. Sweiss ◽  
Linda L. Hushaw
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents

Predictors for progression of two different types of cervical lesions in rheumatoid arthritis treated with biologic agents

2019 ◽  
Vol 24 (2) ◽  
pp. 214-218
Author(s):  
Takashi Kaito ◽  
Shiro Ohshima ◽  
Hiroyasu Fujiwara ◽  
Takahiro Makino ◽  
Shota Takenaka ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents ◽  
Cervical Lesions ◽  
Different Types

THU0129 The Effectiveness of Biologic Agents Concomitant with Tacrolimus in Rheumatoid Arthritis

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 223.2-223
Author(s):  
K. Terabe ◽  
N. Takahashi ◽  
K. Funahashi ◽  
A. Kaneko ◽  
Y. Yabe ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents

scholarly journals Clinical Significance of Serum Levels of ROM (Reactive Oxygen Metabolites) in Patients With Rheumatoid Arthritis Treated With Biologic Agents as a Predictor for the CDAI-, SDAI-, and Boolean-Remission

2021 ◽  
Author(s):  
Arata Nakajima ◽  
Keiichiro Terayama ◽  
Masato Sonobe ◽  
Yorikazu Akatsu ◽  
Junya Saito ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Health Assessment ◽  
Multivariate Logistic Regression Analysis ◽  
Reactive Oxygen ◽  
Serum Levels ◽  
Current Treatment ◽  
Biologic Agents ◽  
Reactive Oxygen Metabolites ◽  
Matrix Metalloproteinase 3 ◽  
Oxygen Metabolites

Abstract We previously showed that reactive oxygen metabolites (ROM) serum levels were associated with the DAS28 in patients with rheumatoid arthritis (RA). In this study, we aimed to investigate whether ROM would be predictive of the CDAI-, SDAI- or Boolean-remission. Fifty-one biologic agents (BA)-naïve RA patients were included in this observational study. Associations between ROM, C-reactive protein (CRP), MMP (matrix metalloproteinase)-3, DAS28-ESR, CDAI, SDAI, and health assessment questionnaire (HAQ) at 12 weeks and the DAS28-, CDAI-, SDAI-, and Boolean-remission at 52 weeks were investigated. The DAS28-, CDAI-, SDAI- and Boolean-remission rates at 52 weeks were 66.7, 52.9, 54.9 and 54.9%, respectively. A multivariate logistic regression analysis revealed that ROM and HAQ at 12 weeks were associated with the CDAI-, SDAI- and Boolean-remission at 52 weeks. Receiver operating characteristic (ROC) analyses demonstrated that the cut-off value for CDAI remission was 389.5 U.Carr, and that for SDAI and Boolean remission was 389.5 U.Carr. ROM at 12 weeks of initial treatment with BAs was a predictor for the CDAI-, SDAI-, and Boolean-remission at 52 weeks. Serum levels of ROM may be a useful biomarker in the current treatment strategy aiming at the early remission of RA.

scholarly journals Rheumatoid arthritis: problems of treatment at the present stage

2018 ◽  
Vol 12 (4) ◽  
pp. 65-70
Author(s):  
N. V. Chichasova
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents ◽  
Control Treatment ◽  
Treat To Target ◽  
Present Stage ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Synthetic Dmards ◽  
Disease Modifying ◽  
Set Up

The possibilities of rheumatoid arthritis therapy have been significantly expanded today. In addition to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic agents (BAs), and a targeted synthetic DMARD, a control treatment strategy has been put into practice.The paper demonstrates successes in the early prescription of csDMARD and the implementation of treat-to-target principles – to achieve the goal after 6 months in 50% of patients receiving subcutaneous methotrexate and 45% of those using a Leflunomide generic. During this therapy, there is a lower need for BAs and targeted synthetic DMARDs. The priority problem is to train general practitioners in methods for the early detection of RA and to set up schools for these patients.

Sign in / Sign up

Export Citation Format

Share Document